News >

Atezolizumab Plus Chemo Improves PFS in Frontline Squamous NSCLC

Jason M. Broderick @jasoncology
Published: Tuesday, Mar 20, 2018

Dr. Sandra Horning

Sandra Horning, MD
The addition of atezolizumab (Tecentriq) to frontline carboplatin and nab-paclitaxel (Abraxane) delayed progression or death compared with chemotherapy alone for patients with advanced squamous non–small cell lung cancer (NSCLC), according to topline findings from the phase III IMpower131 trial released by Genentech (Roche), the manufacturer of the anti–PD-L1 agent.

Previously reported results from a phase Ib trial presented at the 2015 World Conference on Lung Cancer demonstrated the promise of combining frontline atezolizumab with chemotherapy in patients with metastatic NSCLC.1 Patients received atezolizumab at a dose of 15 mg/kg IV every 3 weeks in addition to 1 of 3 chemotherapy doublets: carboplatin paired with paclitaxel, pemetrexed (nonsquamous histology only), or nab-paclitaxel. Treatment continued for 4 to 6 cycles, followed by atezolizumab maintenance therapy until disease progression (and optionally, pemetrexed maintenance in that arm of the trial).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication